Schizophrenia-Like Psychosis Following Right Putaminal Infarction

Kitabayashi, Yurinosuke; Narumoto, Jin; Otakara, Chisato; Choi, Hyungin; Fukui, Kenji; Yamada, Kazutaka

doi:10.1176/jnp.2006.18.4.561

Cited by 15 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings of increased caudate volume in schizophrenia but not in MAP, is consistent with previous work on schizophrenia, where it has been attributed to typical antipsychotic use (Breier et al, 1992;Chakos et al, 1994;Emsley et al, 2023;Jørgensen et al, 2016;Lang et al, 2004). Similarly, increased basal ganglia volumes has been found in several studies of schizophrenia (Emsley et al, 2023;Hokama et al, 1995;Kitabayashi et al, 2006;Mamah et al, 2007;van Erp et al, 2016). The finding that globus pallidus and NAcc volume were increased in schizophrenia compared with MAP, but that right orbitofrontal cortex thickness is decreased in schizophrenia compared with MAP are novel ones, and point to important differences in the neurobiology of these conditions.…”

Section: Discussionsupporting

confidence: 92%

“…Increased caudate volume was observed in schizophrenia but not in MAP, which is a consistent finding in schizophrenia and has been attributed to typical antipsychotic use 6,47–50 . The finding of increased basal ganglia volumes has been replicated in several studies, including putamen volumes in chronic schizophrenia 41,49,51–53 . The finding that globus pallidus and NAcc volume were increased in schizophrenia compared with MAP is a novel one, and may also highlight important differences in the neurobiology between schizophrenia and MAP.…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Subcortical volumes, frontal cortical thickness, and pro-inflammatory cytokines in schizophrenia versus methamphetamine-induced psychosis

Blake,

Williams,

Uhlmann

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Clinical features of schizophrenia and methamphetamine-induced psychosis (MAP) have significant overlap. Schizophrenia is associated with alterations in subcortical volumes, cortical thickness and pro-inflammatory cytokines that may correlate with clinical features. However, analogous work on MAP is lacking. This study compared subcortical volumes, cortical thickness and pro-inflammatory cytokines in individuals with schizophrenia, MAP, and healthy controls. It also assessed associations of neuroimaging measures and cytokine levels with each other, with illness duration and symptom severity in schizophrenia and MAP, and with duration of substance use in MAP. Methods: Participants included 36 individuals with schizophrenia, 27 with MAP, and 32 healthy controls matched for age and sex. Diagnosis was determined using the Structured Clinical Interview for Axis I Disorders and symptom severity was assessed using the Positive and Negative Syndrome Scale. Structural T1-weighted images were acquired using a 3 Tesla magnetic resonance imaging scanner. Serum peripheral cytokine concentrations levels were measured using a multiplex bead array. Analysis of covariance was used to compare measures across groups. Results: Individuals with schizophrenia and with MAP had decreased left amygdala volumes and frontal cortical thickness compared to healthy controls. Individuals with schizophrenia had increased volumes in bilateral caudate, putamen, and nucleus accumbens compared to healthy controls, and increased right globus pallidus and NAcc volumes compared to MAP. Individuals with MAP had increased right orbitofrontal cortical thickness compared to healthy controls. Decreased left amygdala volumes and frontal cortical thickness were significantly associated with longer illness duration in schizophrenia, and with longer duration of methamphetamine use in MAP. There was no significant difference across groups in cytokine levels, and no significant associations of cytokine levels with neuroimaging or clinical measures. Conclusion: This study found overlaps and differences in the neurobiology of schizophrenia and MAP, a finding that is consistent with previous research. Further studies with larger sample sizes and more robust measures are needed to understand immune mechanisms underlying these conditions.

show abstract